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Background: Criticisms that generic measures of health-related quality of life (HRQoL) are not sensitive to impairment
in anorexia nervosa (AN) has spurred the development of disease-specific measures. This study aimed to compare the
psychometric properties of a generic to a disease-specific measure of HRQoL.
Methods: 63 participants with AN completed measures of a generic HRQoL (SF-12), disease-specific HRQoL (Eating
Disorders Quality of Life Questionnaire; EDQOL), functional impairment (days out of role; DOR; Work and Social
Adjustment Scale; WSAS), and eating disorder severity (Eating Disorder Examination; EDE) at baseline, post-treatment,
and 6- and 12-months follow-up. Cronbach’s α was computed for the SF-12 and EDQOL (internal consistency).
Correlations were assessed between SF-12/EDQOL scores and DOR, WSAS, and EDE scores (convergence validity).
Three sets of three multiple linear regressions were performed using SF-12 and EDQOL scores as predictors and
change in DOR, WSAS, and EDE global scores from baseline to (i) post-treatment, (ii) 6-month follow-up, (iii) and
12-month follow-up as dependent variables (predictive validity and sensitivity).
Results: The EDQOL displayed stronger internal consistency (α = 0.92) than the SF-12 (α = 0.80). The SF-12
converged more strongly with DOR and the WSAS (rp = −0.31 to −0.63 vs. 0.06 to 0.70), while the EDQOL converged
more strongly with the EDE (rp = −0.01 to 0.48 vs. -0.01 to −0.37). The SF-12 demonstrated stronger predictive validity
(β = −0.55 to 0.29) and sensitivity to changes in ED severity (β = −0.47 to 0.32).
Conclusions: The SF-12 is a valid and sensitive measure of HRQoL impairment in patients with AN. While the SF-12
may be preferred in research comparing EDs to other populations, and in research and practice as an indicator of
functional impairment; the EDQOL may be preferred by clinicians and researchers interested in HRQoL impairment
specifically associated with an ED and as an additional indicator of ED severity.
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TreatmentBackground
Longer duration of illness is a predictor of treatment re-
sistance and mortality in the eating disorders (EDs) [1,2].
Treatment resistance has traditionally been defined as a
lack of improvement in ED pathology following interven-
tion. However patients who have suffered an ED for years
also suffer from associated impairment in many important
areas of daily life, such as in the social, work, family, and* Correspondence: d.mitchison@uws.edu.au
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reproduction in any medium, provided the orleisure domains. As such, an important end-point to con-
sider in the treatment of enduring EDs is health-related
quality of life (HRQoL) [3]. This is especially the situation
for assessment of outcomes for people with severe and en-
during anorexia nervosa (AN). In these patients treatment
goals are often modified to emphasize improvements in
social and occupational function over full weight recovery
and remission of all ED symptoms [4-8].
Reviews of the relevant literature have found that all
EDs, including ED not otherwise specified (EDNOS),
subclinical EDs, and specific ED features are associatedral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of this research includes an association between AN and
impairment, findings have been mixed, and contention
remains regarding HRQoL in this group. Although AN
is regarded as the most physically and mentally debilitat-
ing of the EDs, a number of clinical and community-
based studies have reported that participants with AN
have less HRQoL impairment than participants with bu-
limia nervosa and binge eating disorder [12-14], and on
some domains (e.g. social functioning) report compar-
able HRQoL to normal controls [13,14].
Such findings have led to a discourse regarding the ac-
curate measurement of HRQoL in the EDs. Criticisms
have been made that generic measures (including the
widely used medical outcome study short forms, the
SF-12 [15] and SF-36 [16]) may not be sensitive to the
true level of impairment associated with EDs, or accur-
ately differentiate between ED diagnostic groups [10,11].
Calls for the development of ED-specific instruments were
made in order to increase the relevance of questions and
domains of HRQoL to people with EDs, thereby increas-
ing the overall sensitivity of HRQoL measurement. This is
not a phenomenon unique to the ED field, but rather mir-
rored a similar disease-specific movement in other health
fields, which began in cancer research [17].
The response was the development of four new instru-
ments, three of which have been identified as having
particularly strong psychometrics [18], including Engel
and colleagues’ EDs quality of life (EDQOL) question-
naire [19]. The stated benefits of these ED-specific instru-
ments include a greater sensitivity to impairment and
responsiveness to change compared to generic HRQoL
measures, in turn resulting in larger effect sizes in analysis.
In practical terms, the greater sensitivity of these specific
measures may translate into knowledge regarding the
minimal change in ED symptomatology required to reflect
meaningful improvement in everyday functioning.
The development and growing preference for ED-
specific HRQoL measures has added to our ability to
measure impairment in EDs, however there are also
limitations that suggest that the use of generic instru-
ments should not be abandoned. For one, ED specific
measures cannot be used to compare EDs to other
mental or physical health disorders. Furthermore, ED-
specific measures attempt to measure HRQoL impair-
ment secondary only to ED symptoms, and as such
must rely on individuals’ ability to partition impairment
caused by the ED versus other psychosocial problems;
an endeavour complicated by the high psychological
and physical comorbidity in people with EDs [20-22].
The respective strengths and limitations of generic
versus specific measures of HRQoL have led to sugges-
tions, both within and outside of the ED field, that there
may be a place for using both types of measures. Whilethis appears sensible advice, no studies to date have
specifically been conducted in order to compare the relative
performance of generic versus disease-specific HRQoL in-
struments in an ED sample. Such an investigation would
provide an evidence-base that will aid the selection of
instruments in future research and clinical practice.
Aims
The current study aimed to compare the psychometrics
of a disease-specific HRQoL measure (EDQOL [19]) to a
generic HRQoL measure (SF-12 [15]), both commonly
used in ED research and practice. The sample was made
of patients with chronic AN participating in a treatment
trial. This allowed for a comparison of the internal
consistency, convergent validity, criterion-related valid-
ity, and sensitivity to predict change in ED pathology of
the EDQoL vs. the SF-12. It also enabled the conten-
tious issue of HRQoL and its measurement in AN to be
addressed. Given our aim was more specifically to test
the claims made that disease-specific measures provide
a more accurate indication of HRQoL, it was hypothe-
sized that the EDQOL would generate stronger internal
consistency, criterion-related and convergent validity,
and sensitivity to change than the SF-12 in this study.
Methods
Participants
Participants were 63 females with long-standing AN,
who were randomly assigned to receive either cognitive
behavioural therapy (CBT) [23] or specialist supportive
clinical management (SSCM) [24]. Participants were eli-
gible if they were female; were 18 years or older; met
DSM-IV [25] criteria for AN (excluding criterion D
amenorrhea, in order to align with the proposed DSM-5
changes); and had an illness duration of at least 7 years
(even if there had been periods of remission). Partici-
pants were excluded from the study if they had a current
manic episode or psychosis; had current alcohol or sub-
stance abuse or dependence; had a significant current
medical or neurological illness, including seizure disorder
(with the exception of nutrition-related alterations) that
impact on weight; were currently engaged in psychother-
apy and not willing to suspend this while participating
in the study; or did not live within or had plans to move
beyond commuting distance from the study site in the
following 12 months. Both treatment arms involved
30 × 50-minute individual treatment sessions provided
over a period of eight months in an outpatient setting.
While treatment addressed ED symptoms, the main goal
was to improve patients’ quality of life. Participants ranged
in age from 20 to 62 years (M = 33.4, SD = 9.6), had a long
duration of AN (M = 16.6 years, SD = 8.5), and were
underweight (M = 16.2 body mass index (BMI; kg/m2),
SD = 1.3). Most participants were diagnosed with AN
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single (n = 36; 57%), did not have children (n = 50; 79%),
were in full-time employment (n = 25; 40%) or study
(n = 10; 16%), and had a graduate or postgraduate degree
(n = 40; 63%).
Measures
Diagnostic measures
Diagnosis at initial assessment was determined using what
is generally considered the gold standard diagnostic inter-
view for EDs, the Eating Disorder Examination (EDE)
[26]. The EDE determines the frequency and severity
of ED symptoms and produces four subscale scores
(Restraint, Eating Concerns, Weight Concerns, and Shape
Concerns) which together contribute to an overall global
score. BMI and frequency of ED behaviours (objective and
subjective binge eating, purging behaviours, and driven
exercise) are also assessed in the EDE. The SCID-I (Struc-
tured Clinical Interview for DSM-IV-TR Axis I Disorders)
[27] was also used to assess for Axis I mental disorder
comorbidity.
Health related quality of life measures
The Medical Outcomes Study (12-item) short-form (SF-12)
[15] and the Eating Disorders Quality of Life Questionnaire
(EDQOL) [19] were administered to assess HRQoL. The
SF-12 is a standardized generic measure, and has been
used widely in research interested in the impairment
associated with physiological and psychological health
conditions. The 12 items contribute to 2 weighted scales,
a Physical Component Summary Scale (PCS) and a
Mental Component Summary Scale (MCS), each with a
normative mean of 50 and standard deviation of 10.
Higher scores indicate higher levels of functioning.
Items on the PCS assess how health is perceived to limit
everyday physical activities, how physical health is per-
ceived to limit social functioning and productivity in
work and other roles, and the extent to which pain is
experienced. Items on the MCS assess how emotional
health is perceived to limit social functioning and prod-
uctivity in work and other roles, and the extent to which
participants feel anxious, depressed, and lethargic. Strong
psychometric properties have been demonstrated and
norms computed for Australian population samples [15,28].
Participants who completed the SF-12 were n = 63 at
baseline, n = 55 (87%) at end of treatment, n = 42 (67%)
at 6-month follow-up, and n = 46 (73%) at the 12-month
follow-up.
The EDQOL was designed as a disease-specific ques-
tionnaire to measure HRQoL in ED patients. It has 25
items that contribute to four subscales (Psychological,
Physical/Cognitive, Work/School, and Financial), which
combined produce an overall quality of life score. Each
item is coded on a five-point scale and asks the participantto rate the extent to which they perceive their ED to affect
their quality of life in different domains. Higher scores
indicate lower ED-HRQoL. Items on the Psychological
subscale assess how the ED is perceived to have im-
pacted on thoughts and feelings about oneself; items on
the Physical/Cognitive subscale assess how the ED is
perceived to have impacted on physical sensations and
cognitive capacity; items on the Financial subscale as-
sess how the ED is perceived to have impacted on finan-
cial status; and items on the Work/School subscale
assess how the ED is perceived to have impacted on
performance at work or school. The authors have
demonstrated good psychometrics for the EDQOL [19].
Participants who completed the EDQOL were n = 63 at
baseline, n = 55 (87%) at end of treatment, n = 43 (68%) at
6-month follow-up, and n = 48 (76%) at the 12-month
follow-up.Measures to assess validity
Convergent validity
Convergent validity refers to the extent that measures of
the same or similar theoretical construct are related to each
other. The Work and Social Adjustment Scale [WSAS; 29]
and days out of role (DOR) question were chosen as in-
dicators of concurrent convergent validity for the SF-12
and EDQOL. The WSAS is a short five-item measure of
disease-specific functional impairment in the domains
of work, home duties, social leisure, private leisure, and
close relationships. It has acceptable psychometric proper-
ties [29]. The DOR question was modelled on questions
employed in the American National Comorbidity Survey
[30]. Specifically, participants were asked: “During the past
four weeks, on how many days, if any, were you unable to
complete your work, study or household responsibilities
because of any problem with your (physical or emotional)
health?” A response between 0 (no days) and 28 (every
day) was required. Research has indicated correlations in
the order of −0.40 to −0.50 between the DOR question
and scores on the PCS and MCS of the SF-12 [31]. The
global scale and subscales of the EDE (described above)
was also used to indicate convergence with ED severity,
with the underlying assumption that poorer HRQoL
should be associated with greater pathology.Predictive criterion-related validity
Predictive criterion-related validity refers to the ability
of scores on a given measure to accurately predict a
future outcome (the criterion). In the present study,
the predictive validity of the SF-12 and EDQOL ad-
ministered at baseline was tested against the criterion
of change in DOR and WSAS scores from baseline to
post-treatment.
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The sensitivity of a measure refers to the extent to which
changes in scores of the measure predicts changes in an-
other measure. To assess the sensitivity of the SF-12 and
EDQOL to changes in ED pathology, the ability of the
SF-12 and EDQOL to predict baseline to post-treatment
changes in the EDE global score was assessed.
Procedure
The study was approved by the Human Research Ethics
Committee of the University of Sydney (Protocol No:
9669). Participants were recruited from July 2007 through
November 2010 by advertising to clinicians, clinics treat-
ing people with EDs, and on generic websites. After tele-
phone screening (N = 159) to determine eligibility, 73
(46%) eligible participants were invited for in-person as-
sessment. Respective site study coordinators described
the protocol in detail to these eligible participants be-
fore written informed consent was obtained and the
assessments conducted. Eighty-six percent (N = 63) of
eligible participants agreed to randomization. Participants
were assigned to and received either CBT or SSCM. In
addition to the pre-treatment assessment, participants
were assessed immediately post-treatment, and 6- and
12-months following the end of treatment. Assessments
were conducted by trained psychologists blind to treat-
ment assignment, and at a place of convenience to the
participant which was not the place of treatment.
Data analysis
The Statistical Package for the Social Sciences (SPSS)
version 20.0 was used to carry out analyses. Descriptive
statistics of baseline demographic information were com-
puted, and compared between the CBT and SSCM groups
using student t-tests (age, BMI, duration of illness) and
chi-square tests (AN subtype, relationship status, employ-
ment/study status, children status, highest education level
achieved). Given no significant differences were observed
on any of these variables (all p > 0.05), the CBT and SSCM
groups were grouped together in subsequent baseline ana-
lyses. In analyses that used post-treatment data, treatment
assignment was entered as a covariate.
To assess internal consistency, Cronbach’s α was com-
puted on the baseline data for the subscale and total
scores of the SF-12 and EDQOL. Validity and sensitivity
analyses were run with and without DSM-IV-TR Axis I
comorbidity as a covariate. Pearson product–moment cor-
relations (rp) were computed to facilitate validity analyses.
To assess concurrent convergent validity, baseline WSAS
and DOR scores were correlated with baseline SF-12 and
EDQOL subscale scores. To assess concurrent conver-
gence with ED severity, the baseline EDE subscale and
global scores were correlated with the baseline SF-12 and
EDQOL subscale scores. To assess predictive criterion-related validity, incremental change scores from baseline
to post-treatment for the DOR and WSAS were com-
puted, and then regressed against baseline SF-12 and
EDQOL subscale scores. To assess the sensitivity to pre-
dict change in ED severity, incremental change in the EDE
global score from baseline to post-treatment was com-
puted and regressed against baseline SF-12 and EDQOL
subscale scores. Analyses were considered significant at
p < 0.05. Post-hoc power analyses using the PASS 11
software [32] revealed adequate power (0.8) to detect
medium-sized correlations for the convergence validity
analyses, and R2 coefficients in the order of 0.28 - 0.35
for the predictive validity and sensitivity analyses.
Results
Treatment effects for the randomized controlled trial,
within which the current study is embedded, have been
analysed and are reported elsewhere [8].
Internal consistency
Cronbach’s α for the total EDQOL scale was 0.92 and
for the total SF-12 scale was 0.80. For the EDQOL sub-
scales the α-coefficients were: 0.91 (Psychological), 0.86
(Physical/Cognitive), 0.73 (Work/School), and 0.81 (Finan-
cial). For the SF-12 summary scales the α-coefficients
were: 0.71 (PCS) and 0.80 (MCS).
Validity
Convergence with functional impairment
The Pearson Product Moment correlations to establish
convergent validity are presented in Table 1. Most corre-
lations between the SF-12/EDQOL subscales and the
WSAS scale and DOR question were significant, and
ranged from moderate to strong (rp > 0.30), indicating
convergence with measures of functional impairment.
Correlations for the SF-12 summary scales with the WSAS
and DOR ranged between −0.31 to −0.63. Correlations for
the EDQOL subscales with the WSAS and DOR ranged
between 0.06 to 0.70. When partial correlations were
computed, controlling for Axis I comorbidity, the strength
of these correlations reduced (see Table 1).
Convergence with eating disorder severity
Table 1 also contains the correlations of the SF-12/EDQOL
with the EDE global and subscales. These correlations
were also mostly significant and moderate to strong, indi-
cating convergence with a measure of ED severity. The
correlations for the SF-12 summary scales with the EDE
global scale and subscales ranged between 0.01 to −0.37.
The correlations for the EDQOL subscales with the EDE
global and subscales ranged between −0.01 to 0.48. In
order to assess for any effect of age on convergence with
ED severity, the analyses were re-run as partial correla-
tions controlling for age. No effect of age was found.
Table 1 Convergent validity of the SF-12 and EDQOL
SF-12 PCS SF-12 MCS EDQOL psychological EDQOL physical/cognitive EDQOL financial EDQOL work/school
No Covariates
WSAS −0.36** −0.63** 0.70** 0.66** 0.29* 0.59**
DOR −0.31* −0.35** 0.19 0.53** 0.06 0.51**
EDE-G −0.01 −0.37** 0.48** 0.41** 0.15 0.42**
EDE-R 0.12 −0.31** 0.41** 0.28* 0.16 0.24
EDE-EC −0.23 −0.33** 0.46** 0.45** 0.19 0.42**
EDE-WC 0.03 −0.36** 0.40** 0.33** −0.01 0.38**
EDE-SC 0.01 −0.25* 0.35** 0.31* 0.17 0.39**
Covarying for Axis I Comorbidity
WSAS −0.25 −0.43** 0.57** 0.52** 0.28* 0.51**
DOR −0.25 −0.08 0.14 0.45** −0.08 0.31*
EDE-G 0.11 −0.05 0.25 0.20 −0.05 0.18
EDE-R 0.21 −0.13 0.26 0.12 0.03 0.08
EDE-EC −0.10 −0.09 0.31* 0.29* 0.05 0.23
EDE-WC 0.13 0.04 0.09 0.09 −0.22 0.08
EDE-SC 0.07 0.03 0.14 0.16 −0.02 0.19
**p < 0.01, *p < 0.05; SF-12 = Medical Outcomes Study Short Form; PCS = Physical Component Summary Scale; MCS = Mental Component Summary Scale;
EDQOL = Eating Disorders Quality of Life Questionnaire; WSAS = Work and Social Adjustment Scale; DOR = days out of role; EDE = Eating Disorders Examination;
R = Restraint subscale; EC = Eating Concerns subscale; WC = Weight Concerns subscale; SC = Shape Concerns subscale; G = Global scale.
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bidity resulted in a loss of almost all significant correla-
tions (see Table 1).
Predictive criterion-related validity
The SF-12 and EDQOL subscales were entered as predic-
tors into multiple linear regressions (MLRs) with change
in DOR (n = 45) and WSAS (n = 46) from baseline to
post-treatment as the dependent variables, for participants
with complete data (see Table 2). The MCS of the SF-12
emerged as the only significant independent predictor
of both change in DOR (rp = −0.31, p = 0.02) and
change in the WSAS (rp = −0.55, p < 0.001) scores by
post-treatment. Table 2 also shows post-hoc MLR ana-
lyses that were run on the data for the two follow-up
time points at 6-months and 12-months post treatment.
The MCS of the SF-12 remained the sole predictor of
change in WSAS scores at both the 6-month (rp = −0.51,
p < 0.001) and 12-month (rp = −0.44, p = 0.00) follow-up.
The Work/School (rp = 0.31, p = 0.03) and Financial
(rp = −0.21, p = 0.11) EDQOL subscales predicted change
in DOR by the 6-month follow-up and the Work/School
subscale remained a significant predictor of change in
DOR after 12 months (rp = 0.29, p = 0.04). When these
analyses included Axis I comorbidity as a covariate, few
differences emerged (see Table 2): the MCS of the SF-12
no longer predicted change in DOR immediately post-
treatment, whereas the Financial subscale of the EDQOL
did; and there were no significant predictors of change in
DOR by the 12-month follow-up.Sensitivity to change in eating disorder pathology
A MLR was conducted with change in the global EDE
score from baseline to post-treatment as the dependent
variable (see Table 3), and using data from participants
with complete data (n = 45). Baseline scores on the MCS
of the SF-12 (rp = −0.34, p = 0.01) emerged as the stron-
gest independent predictor, followed by treatment assign-
ment (rp = −0.25, p = 0.05). Post-hoc analyses of the
follow-up data revealed that the MCS of the SF-12
(rp = −0.24, p = 0.07) and treatment assignment (rp = −0.23,
p = 0.08) remained significant predictors of change in the
global EDE scale from baseline to 6-month follow-up
(n = 38), while the PCS of the SF-12 (rp = 0.32, p = 0.02)
emerged as the sole independent predictor of change in
the EDE global score after 12 months (n = 41, see Table 3).
These variables remained significant predictors when
analyses included Axis I comorbidity as a covariate (see
Table 3).
Discussion
The aim of this study was to examine and compare the
psychometric properties of a generic measure (the SF-12)
to a disease-specific measure (the EDQOL) of HRQoL in
a clinical sample of patients with AN. It was hypothesised
that the EDQOL would out-perform the SF-12 in terms
of its reliability, validity, and sensitivity to predict changes
in ED pathology. This hypothesis was only partially sup-
ported. Consistent with the hypothesis, the EDQOL dem-
onstrated stronger internal consistency than the SF-12
and also converged more consistently with indicators of
Table 2 Multiple linear regression models using the SF-12 and EDQOL as predictors of change in functional impairment
(predictive validity)
Dependent Significant predictors B SE (B) β t p
Without Axis I Comorbidity as a covariate
DOR change: baseline to post-treatment SF-12 MCS −0.23 0.11 −0.31 −2.10 0.04
R2adj = 0.07
DOR change: baseline to 6-month follow-up EDQOL Work/School 5.20 2.07 0.40 2.51 0.02
EDQOL Financial −4.18 2.12 −0.31 −1.97 0.06
R2adj = 0.14
DOR change: baseline to 12-month follow-up EDQOL Work/School 2.71 1.49 0.29 1.82 0.08
R2adj = 0.06
WSAS change: baseline to post-treatment SF-12 MCS −0.43 0.10 −0.55 −4.34 <0.001
R2adj = 0.28
WSAS change: baseline to 6-month follow-up SF-12 MCS −0.38 0.10 −0.51 −3.61 0.001
R2adj = 0.24
WSAS change: baseline to 12-month follow-up SF-12 MCS −0.33 0.11 −0.44 −3.00 0.01
R2adj = 0.17
With Axis I Comorbidity as a Covariate
DOR change: baseline to post-treatment Axis I Comorbidities 6.97 2.62 0.40 2.67 0.01
EDQOL Financial −4.29 2.06 −0.31 −2.08 0.04
R2adj = 0.14
DOR change: baseline to 6-month follow-up EDQOL Work/School 4.91 2.33 0.35 2.11 0.04
EDQOL Financial −4.36 2.16 −0.34 −2.02 0.05
R2adj = 0.12
DOR change: baseline to 12-month follow-up - - - - - -
R2adj = 0.00
WSAS change: baseline to post-treatment SF-12 MCS −0.41 0.10 −0.52 −3.96 <0.001
R2adj = 0.25
WSAS change: baseline to 6-month follow-up SF-12 MCS −0.36 0.11 −0.48 −3.23 0.00
R2adj = 0.21
WSAS change: baseline to 12-month follow-up SF-12 MCS −0.34 0.12 −0.43 −2.85 0.01
R2adj = 0.16
R2adj = variance in the dependent variable accounted for by the predictor variable(s), adjusting for statistical shrinkage; SF-12 = Medical Outcomes Study Short
Form; PCS = Physical Component Summary Scale; EDQOL = Eating Disorders Quality of Life Questionnaire; DOR = days out of role; WSAS = Work and Social
Adjustment Scale.
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sistently with indicators of functional impairment, and
was better able to predict changes in both functional im-
pairment and ED severity across time.
The development of ED-specific instruments for HRQoL
was in part spurred by a concern that generic measures
were not sufficiently sensitive to impairment in the EDs,
and particularly in AN. The current study has assessed
HRQoL using both a generic and an ED-specific instru-
ment in a sample diagnosed with AN. Contrary to our
hypotheses, the generic measure of HRQoL – the SF-12 –
was found to be more predictive of changes not only in
functional impairment but also in ED pathology, com-
pared to the disease-specific EDQOL. Thus this studyhas challenged previous assertions by demonstrating
that a generic measure of HRQoL is valid and sensitive
to pathology in a clinical ED sample.
The SF-12 may also be a more accurate measure of
HRQoL than the EDQOL, as it showed stronger conver-
gence with the WSAS and DOR question. All subscales
of the SF-12, but not of the EDQOL, were significantly
correlated with the WSAS scale and the DOR question.
The WSAS and DOR question are indicators of func-
tional impairment, a construct closely and theoretically
aligned to HRQoL. When functional impairment (in-
cluding the ability to attend work) is a result of poor
health, as is often the case in patients with AN, then it
would be expected to be highly correlated with HRQoL.
Table 3 Multiple linear regression models using the SF-12 and EDQOL subscales as predictors of change in eating
disorder pathology
Dependent Significant predictors B SE (B) β t p
Without Axis I Comorbidity as a Covariate
EDE change: baseline to post-treatment SF-12 MCS −0.05 0.01 −0.47 −3.36 0.002
Treatment assignment −1.02 0.35 −0.40 −2.88 0.006
R2adj = 0.23
EDE change: baseline to 6-month follow-up SF-12 MCS −0.04 0.02 −0.36 −2.20 0.04
Treatment assignment −0.86 0.40 −0.35 −2.13 0.04
R2adj = 0.12
EDE change: baseline to 12-month follow-up SF-12 PCS 0.05 0.02 0.32 2.11 0.04
R2adj = 0.08
With Axis I Comorbidity as a Covariate
EDE change: baseline to post-treatment SF-12 MCS −0.04 0.01 −0.43 −2.85 0.01
Treatment assignment −0.84 0.36 −0.35 −2.31 0.03
R2adj = 0.16
EDE change: baseline to 6-month follow-up Treatment assignment −0.81 0.44 −0.33 −1.87 0.07
SF-12 MCS −0.03 0.02 −0.32 −1.82 0.08
R2adj = 0.08
EDE change: baseline to 12-month follow-up SF-12 PCS 0.05 0.03 0.33 2.11 0.04
R2adj = 0.08
R2adj = variance in the dependent variable accounted for by the predictor variable(s), adjusting for statistical shrinkage; SF-12 = Medical Outcomes Study Short
Form; PCS = Physical Component Summary Scale; EDQOL = Eating Disorders Quality of Life Questionnaire; EDE = Eating Disorders Examination (global scale).
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impairment has important public health implications, and
as such measures that are able to capture functional im-
pairment contribute to a greater understanding of the
overall burden of EDs. On the other hand, the EDQOL
had stronger convergence with ED severity. All EDQOL
subscales (except Financial) had significant correlations
with the EDE scales, whereas only the MCS of the SF-12
was correlated with the EDE. As such, the EDQOL can be
helpful in understanding the severity of an ED, given that
high EDQOL scores are closely associated with high EDE
scores. The relative convergence of the SF-12 and EDQOL
with functional impairment versus ED pathology may be
expected based on the specificity of the instruments. The
generic nature of the SF-12 allows it to assess overall im-
pairment in functioning - not only that perceived to stem
from an ED - and as such is expected to align with other
generic measures of impairment. Similarly, because the
EDQOL was designed for people with EDs, it may be ex-
pected to align more closely with ED measures. Interest-
ingly, once Axis I comorbidity was controlled for, many of
the correlations with measures of functional impairment
and ED severity were lost. This may signify that comorbid
disorders accounted for much of the association with
impairment and severity. It may also indicate that with
greater ED severity the likelihood of having a comorbiddisorder increases, and that this is associated with over-
all greater impairment.
The MCS of the SF-12 was consistently predictive of
scores on the WSAS following treatment. However while
the MCS was also predictive of DOR immediately post-
treatment, it was not so at the follow-up time-points, 6
and 12 months post-treatment. Rather, the EDQOL (spe-
cifically the Work/School and Financial subscale) emerged
as a significant predictor of DOR 6 and 12 months follow-
ing treatment. In interpreting these findings, poorer men-
tal wellbeing and functioning in work or school prior to
treatment was associated with greater improvements in
the occupational, academic, household, and interper-
sonal domains post-treatment. This likely demonstrates
that those who are functioning less well prior to treat-
ment have more room to improve, and this is able to be
reflected particularly well by the MCS of the SF-12, but
also to some extent on the Work/School and Financial
subscales of the EDQOL.
A limitation of the current study may have been the
use of the SF-12 rather than the longer scale from which
it was derived, the SF-36, which may be more compar-
able to the EDQOL in design. A more balanced compari-
son of generic vs. disease-specific instruments may have
used the EDQOL and SF-36, both of which are similar
in length and have multiple subscales. Further, the SF-36
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SF-12 [33]. Test-retest reliability is an important psy-
chometric indicator that we were unable to assess in
the current study. Although this could have been achieved
by adding another pre-treatment assessment point, this
was decided against in order to limit participant burden in
the randomized controlled trial in which the current study
was embedded. Another limitation with the design of this
study is that it did not allow for comparisons with other
diagnostic subgroups or healthy controls. These compari-
sons would be of interest in future research since several
previous studies have found that compared to people with
other ED diagnoses or in the general community, people
with AN demonstrate less or commensurate impairment
in HRQoL [12-14]. The omission of amenorrhea as a cri-
terion for AN may be seen as a limitation. This was done
in order to be more consistent with the proposed DSM-5
criteria for AN and as such to have greater relevance to
future studies using these criteria. It is acknowledged how-
ever that this may have resulted in a sample that differed
from previous studies’ samples based on DSM-IV criteria.
Participants in the current study may also have been older
than those in previous AN studies. This was influenced by
the aims of the treatment trial, which was to assess treat-
ment efficacy in participants with long-standing AN.
Finally, it is important to emphasise that our findings
relate specifically to the population of chronic AN, and
that although our findings are possibly relevant to other
populations, this would need to be verified by future
research.
In regards to advice for researchers and practitioners
who wish to measure HRQoL, the decision ultimately
comes down to the design and purpose of measurement.
Should cross-comparisons be desired with the general
population or other diagnostic groups, then generic mea-
sures, such as the SF-12 or SF-36 should be applied. How-
ever, the implication from this study is that if the sample
of interest is AN-only then either the SF-12 or EDQOL
could be used. If users require a measure that will also
provide an indication of ED severity, then the EDQOL
could be relatively more useful. Conversely, if the aim is
to provide an indication of functional impairment, then
the SF-12 may be the preferred option. On the other
hand, and in line with previous suggestions, if time and
resources permit, generic and disease-specific measures
may be used in tandem.
Conclusion
Our findings indicate that the EDQOL, a disease-specific
measure of HRQoL, and the SF-12, a generic measure of
HRQoL, are reliable and valid measures; and that the
SF-12 is also sensitive to changes in pathology in a sample
of patients with enduring AN. This provides evidence
against previous assertions that generic measures ofHRQoL are not sufficiently sensitive to impairment
associated with AN. Both the SF-12 and the EDQOL
are useful measures of HRQoL for practitioners and
researchers who work with patients with AN.
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